Signatera Genome: Unlocking the next level of ultrasensitive MRD detection with Phased Variant technology

NateraConnect 30 second captioned

Marci Invasive Lobular Breast Cancer Patient

Signatera Explainer

MODERN Part 3, CIRB

MODERN Part 2, CIRB

MODERN Part 1, CIRB

Signatera PRIMR

What are clinical applications of Signatera

Partnering in Survivorship: The Oncology-OB/GYN connection in breast cancer surveillance

Signatera MRD Testing for NSCLC Patient Management

Personalized ctDNA testing in Urothelial Cancer

Signatera™ MRD Testing for Head and Neck Cancer

New data. Better insight. The future of precision breast cancer management

An MRD-guided approach to advancing treatment strategies in gynecologic cancer

Shaping the future of skin cancer: Tumor-informed ctDNA-guided interventions

From Detection to Decision-Making: Utility of Signatera in Complex GI & Hepatobiliary Malignancies

Dr. Ari Rosenberg SINERGY Data Summary

Dr. Ari Rosenberg from the University of Chicago gives a summary on the SINERGY Trial data that he presented during an oral plenary session at MHNCS.

Meet Jon, Muscle-Invasive Bladder Cancer (MIBC) Survivor and Signatera Patient